Mylan Cautiously Optimistic About India Market Following Approval Of Agila Acquisition

26 Sep 2013

• By Vikas Dandekar

The global generics giant hopes to take a quantum leap in its business prospects. But Mylan remains cautious about striking business deals in India in the wake of changing pricing and policy dynamics.

MUMBAI – Mylan NV President Rajiv Malik is in a sweet spot. The $6.8 billion Pittsburgh-headquartered generics drug maker is nearing windfall gains arising from a few hard-pursued programs. For one, the Indian government gave the green light to its $1.6 billion acquisition of Agila Specialties Pvt. Ltd. after looming doubts it would be approved.

Once integrated, Mylan hopes to gain a significant lead in the global injectables market via Agila’s pipeline of products (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.